CLINICAL TRIALS PROFILE FOR NALBUPHINE HYDROCHLORIDE

All Clinical Trials for NALBUPHINE HYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00155233 ↗	Interaction Between Nalbuphine and Morphine in PCA	Unknown status	National Taiwan University Hospital	Phase 4	2005-01-01	1. Nalbuphine is opioid mu receptor antagonist and kappa receptor agonist 2. This study was designed to investigate the interaction between nalbuphine and morphine
NCT00200564 ↗	Ketamine and Postoperative Analgesia in Children	Unknown status	Nantes University Hospital	Phase 4	2004-02-01	The benefit of small doses of ketamine has been demonstrated for postoperative analgesia in adults but remains unproved in children. The investigators' purpose is to evaluate the effects of continuous intravenous small doses of ketamine versus placebo to improve the quality of postoperative analgesia in children (6 months to 6 years of age). Caudal anesthesia is performed for intraoperative analgesia and all children receive paracetamol, a non-steroidal anti-inflammatory and continuous intravenous nalbuphine.
NCT00323154 ↗	Nalbuphine for the Treatment of Opioid Induced Pruritus in Children	Completed	University of British Columbia	Phase 3	2004-03-01	Itching is a frequent and disturbing side effect of the use of pain medication such as morphine. In the post-operative period, it can be more distressing to pediatric patients than their pain. The current first line treatment, an antihistamine (Benadryl), has a low efficacy. This treatment causes sleepiness and may be dangerous when used in combination with other drugs. Nalbuphine has analgesic properties similar to morphine as well as the ability to reverse some morphine-induced side effects, such as respiratory depression and itching. Nalbuphine has been used effectively for patients undergoing Caesarean sections. However, the effectiveness of nalbuphine in the pediatric population has not been investigated. We want to determine the efficacy of nalbuphine in the treatment of itching after morphine for postoperative pain relief. We will use a novel method to measure the effect of the treatment using an intensity scale before and after the drug, to determine the intensity difference.
NCT00499746 ↗	The Discriminative Effects of Tramadol in Humans	Completed	National Institute on Drug Abuse (NIDA)	Phase 1/Phase 2	2007-11-01	This research is part of a set of studies whose purpose is to test whether tramadol can be used for the treatment of opioid addiction. Tramadol is already available in the United States as a pain medicine marketed as Ultram. It has effects similar to morphine, and it may also have effects similar to other drugs like stimulants. The doses of tramadol used in this study are higher than those generally used for the treatment of pain. To be in this study a participant must be a user of opioids (drugs like heroin) and stimulants (drugs like cocaine), but cannot be addicted to either. The person must be between 21-55 years old, and generally healthy. Up to 12 people will take part in this study.
NCT00707824 ↗	Epidural Nalbuphine for Postcesarean Epidural Morphine Induced Pruritus	Completed	Mahidol University	Phase 4	2000-06-01	Can epidural nalbuphine reduce incidence or severity of epidural morphine induced pruritus in patient undergoing cesarean section?
NCT00716807 ↗	Efficacy of Nalbuphine and Naloxone Administered as Nose Sprays in the Treatment of Orofacial Pain	Terminated	University of California, San Francisco	N/A	2008-01-01	Patients with chronic masticatory muscle pain (i.e., pain greater than three months) or patients with burning mouth syndrome participate in this study. The aim of the study is to compare the pain killing effectiveness of nalbuphine, a narcotic pain killer, administered with either placebo or naloxone, a drug used to treat opiate overdose. A second goal is to determine if there are sex differences in these two drug regimens. Drugs will be administered with single-use intranasal spray devices. All participants will receive two sprays (one spray per nostril). One of the two sprays will be nalbuphine (5 mg). The other spray will be naloxone in half the participants and placebo in the other half.

Clinical Trial Conditions for NALBUPHINE HYDROCHLORIDE

Condition Name

Condition Name for NALBUPHINE HYDROCHLORIDE
Intervention	Trials
Postoperative Pain	13
Pain, Postoperative	11
Post Operative Pain	9
Pain	7

Condition MeSH

Condition MeSH for NALBUPHINE HYDROCHLORIDE
Intervention	Trials
Pain, Postoperative	45
Pruritus	9
Emergence Delirium	8
Vomiting	7

Clinical Trial Locations for NALBUPHINE HYDROCHLORIDE

Trials by Country

Trials by Country for NALBUPHINE HYDROCHLORIDE
Location	Trials
United States	89
Egypt	52
China	31
Pakistan	17
Taiwan	16

Trials by US State

Trials by US State for NALBUPHINE HYDROCHLORIDE
Location	Trials
California	7
Ohio	5
North Carolina	5
Florida	5
Texas	4

Clinical Trial Progress for NALBUPHINE HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for NALBUPHINE HYDROCHLORIDE
Clinical Trial Phase	Trials
PHASE4	13
PHASE3	5
PHASE2	13

Clinical Trial Status

Clinical Trial Status for NALBUPHINE HYDROCHLORIDE
Clinical Trial Phase	Trials
Completed	60
RECRUITING	43
Not yet recruiting	19

Clinical Trial Sponsors for NALBUPHINE HYDROCHLORIDE

Sponsor Name

Sponsor Name for NALBUPHINE HYDROCHLORIDE
Sponsor	Trials
Assiut University	21
Ain Shams University	13
Trevi Therapeutics	13

Sponsor Type

Sponsor Type for NALBUPHINE HYDROCHLORIDE
Sponsor	Trials
Other	146
Industry	26
OTHER_GOV	11

NALBUPHINE HYDROCHLORIDE Market Analysis and Financial Projection

Last updated: April 28, 2026

Nalbuphine Hydrochloride: Clinical Trials Update, Market Analysis and 2026–2035 Projection

What is the current clinical-development status for nalbuphine hydrochloride?

Nalbuphine hydrochloride is an established opioid analgesic with long-standing clinical use across multiple geographies. Public registries show limited active interventional trial activity specifically for “nalbuphine hydrochloride” under that exact name, with most contemporary research activity clustering around (1) formulation, (2) comparative analgesia, and (3) perioperative pain protocols in mixed opioid regimens rather than new “nalbuphine hydrochloride” submissions. This pattern is consistent with a product that is widely marketed and therefore faces fewer brand-new pivotal development programs.

Clinical activity snapshot (public registry behavior)

• Interventional trials: Mostly intermittent, with sparse counts relative to actively developed new molecular entities.
• Common focus areas: acute pain (perioperative), emergency/analgesia protocols, and post-marketing comparative studies.
• Regulatory novelty: When new studies appear, they generally support label refinement (route/dose/timing) or protocol positioning rather than drug substance discovery.

Implication for pipeline expectation

• Near-term pipeline value is more likely to come from lifecycle work (formulation, labeling, country expansions) than from “new” drug approvals, because the active ingredient already has broad clinical recognition and prescribing history.

---

What does the market look like for nalbuphine hydrochloride today?

Nalbuphine hydrochloride competes in the hospital and acute-care analgesia segment, where clinicians balance analgesic efficacy against respiratory depression risk profiles. As a mixed agonist-antagonist (κ-opioid agonist, μ-opioid partial agonist/antagonist activity depending on context), it is positioned as an option in perioperative and acute pain pathways and in some substitution settings where clinicians consider opioid-receptor activity profiles.

Demand drivers

• Hospital-based pain management volumes (surgeries, emergency department presentations).
• Perioperative analgesia protocols that use injectable opioids as first-line agents.
• Generics availability that keeps price and access favorable versus newer branded analgesics.
• Formulary adoption and substitution through tendering practices, where established molecules win based on procurement cost and supply certainty.

Commercial structure

• Product supply: nalbuphine hydrochloride typically trades as a mature, generically accessible injectable analgesic rather than a single protected branded franchise product.
• Buyer profile: hospitals, surgery centers, and national procurement bodies; not primarily community retail channels.

---

Where is value most likely to accrue in nalbuphine’s commercial system?

Because the active ingredient is mature, value accrues through execution levers rather than breakthrough science.

Most common value channels

• Tender economics: sustained procurement at competitive cost and reliable supply.
• Formulary inclusion: continued placement in hospital opioid pathways.
• Packaging and concentration strategy: dosing convenience for anesthesia workflows.
• Regulatory maintenance: keeping labels aligned with clinical practice and country-specific restrictions.

---

How should investors and R&D teams project nalbuphine hydrochloride revenues through 2026–2035?

A precise global forecast requires granular country-level pricing, tender cadence, and volume by indication, which are not available in a consistent single dataset here. What can be produced is a structured projection framework tied to realistic market mechanics for a mature injectable opioid.

Projection approach for mature generics (what moves the numbers)

1. Volume trend: increases with hospital procedure volumes and emergency presentations.
2. Price trend: typically declines or stays flat in generics due to competition and procurement pressure.
3. Share trend: stable or shifts as supply contracts rotate and as protocols adapt.
4. Regulatory risk: opioid policy can change restrictions, but nalbuphine’s established status reduces approval-process risk.

Base-case scenario (global market index)

• 2026–2030: low growth by value, driven by volume offsets as pricing stays under pressure.
• 2031–2035: modest value growth, with gradual share stability and continued tender competition.

Base-case CAGR (value terms): 2% to 4%

• Why this range fits a mature generic injectable: volume growth can outpace price erosion in many markets, but competitive pricing caps upside.

Bull-case scenario (policy-neutral expansion + protocol durability)

• 2026–2035: higher share retention in acute care and incremental uptake in perioperative settings.
• Bull-case CAGR: 4% to 6%

Bear-case scenario (opioid restriction tightening + stronger procurement price compression)

• 2026–2035: faster price erosion and reduced tender allowances in some jurisdictions.
• Bear-case CAGR: 0% to 2%

---

Market projection table (index-based, actionable ranges)

Use this table to underwrite planning assumptions for revenue growth, working capital needs, and supply chain capacity.

Period	Base-case value CAGR	Expected dynamics	Bull-case value CAGR	Bear-case value CAGR
2026–2030	2% to 4%	Volume offsets pricing pressure	4% to 6%	0% to 2%
2031–2035	2% to 4%	Tender stability, protocol persistence	3% to 5%	-0.5% to 1.5%

---

What are the highest-probability competitive moves over the next 5 to 10 years?

Because the molecule is mature, competition is driven by manufacturing economics and tender logistics.

Most likely moves

• Capacity-driven price tightening as additional generics compete for hospital contracts.
• Lifecycle packaging changes (convenience sizes, concentration standardization).
• Regional expansion where procurement frameworks favor established molecules.
• Contract-based distribution that locks volumes to distributors and tenders.

Less likely moves

• New chemical entity approval cycles specifically for nalbuphine hydrochloride are unlikely to dominate the decade, absent major new clinical findings that change standard of care.

---

Key risks that can bend the forecast

Regulatory and policy

• Opioid stewardship rules can affect prescribing flexibility, stocking requirements, and formularies.

Supply chain and quality

• Sterile injectable supply disruptions can cause lost tenders even if demand exists.

Pricing and contracting

• Procurement bodies can force step-down pricing, reducing margins and shifting competitive advantage to the lowest landed cost suppliers.

---

What does this mean for R&D prioritization and investment underwriting?

For a mature injectable opioid, the highest-return R&D typically targets commercial bottlenecks rather than discovery.

R&D priorities with strongest commercial linkage

• Formulation stability and manufacturing robustness to protect supply continuity in tenders.
• Concentration and pack-size optimization aligned to dosing workflows.
• Country-specific label refinement that reduces physician hesitation and supports formulary committees.

Investment thesis framing

• Underwrite nalbuphine as a cash-yielding mature product with growth driven by volume and contract execution, not by platform-style innovation.

---

Key Takeaways

• Nalbuphine hydrochloride is a mature injectable opioid with limited contemporary interventional pipeline activity focused on protocol and lifecycle-type work rather than new drug approvals.
• Market demand is primarily hospital- and procedure-driven, supported by perioperative pain management pathways and governed by tender-based procurement economics.
• A practical global projection for 2026–2035 is 2% to 4% value CAGR in the base case, with 4% to 6% bull and 0% to 2% bear depending on pricing pressure and opioid-policy/tender dynamics.
• Commercial advantage will come from supply reliability, tender pricing, and label/protocol fit, not from a new mechanism-of-action storyline.

---

FAQs

1) Is there a major nalbuphine hydrochloride clinical catalyst expected in the near term?

Public-facing clinical activity for nalbuphine is more consistent with intermittent lifecycle and comparative/protocol studies than with a concentrated set of pivotal catalysts.

2) What indication class drives most demand for nalbuphine hydrochloride?

Acute pain management, especially perioperative and hospital analgesia pathways where injectable opioids are used in standardized protocols.

3) How sensitive is nalbuphine’s market to pricing?

High. Generics and procurement tenders typically exert steady downward pressure on per-unit pricing, making volume gains and contract retention crucial.

4) What is the biggest risk to revenue projections?

Procurement price compression and opioid policy restrictions that tighten stocking or prescribing allowances in specific jurisdictions.

5) What investment or R&D efforts produce the strongest commercial impact?

Manufacturing robustness, stable supply, and pack-size/concentration optimization that aligns to hospital workflow and tender needs.

---

References

[1] ClinicalTrials.gov. Nalbuphine hydrochloride search results and study records. https://clinicaltrials.gov/